Quantcast

Latest Chiron Corp. Stories

2009-02-11 09:06:12

Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.These are the findings of two large international clinical trials presented today at the Conference on Retroviruses and...

2006-03-16 09:50:00

CHICAGO (Reuters) - Chiron Corp. on Thursday said it is recalling and withdrawing its measles, mumps and rubella vaccine, MORUPAR, from Italian and developing world markets because it may be associated with a higher rate of adverse side effects than other such vaccines. The adverse events on which the recall and withdrawal are based are within a range of those commonly associated with vaccines, such as fever, allergic reactions and swelling of the glands, Chiron said. As a result of the...

2005-12-01 19:11:58

By Susan Heavey WASHINGTON (Reuters) - A test to screen blood, organ and tissue donors for the West Nile virus won U.S. approval after two years of testing in the nation's blood banks, Food and Drug Administration officials said on Thursday. The Procleix WNV Assay was developed by Gen-Probe Inc. and marketed by Chiron Corp. West Nile virus is most-often transmitted by mosquitoes, but there have been 30 documented cases of people who most likely got the illness from a blood...

e68da0824b1d88dfca724e1c7ee62cd81
2005-11-15 19:07:08

WASHINGTON -- Companies are proposing a change in how they make flu vaccine that they believe will improve the nation's ability to fight the viruses and modernize the process. Basing production on cell cultures in a laboratory rather than chicken eggs, the traditional source of flu vaccine for a half-century, could make the vaccine more expensive. The Food and Drug Administration has raised concerns that other viruses or cancer cells could make their way from the cell cultures to the vaccine...

2005-11-10 16:21:49

By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - Unexpectedly high demand for flu shots means some U.S. clinics have run out early, but the country will have plenty of influenza vaccine this year, health officials said on Thursday. They said the flu season had not taken off yet and Americans would have time to be vaccinated before the threat peaked, generally in February or March in the United States. "So far at least 71 million doses of influenza vaccine have...

2005-10-27 14:05:27

WASHINGTON (Reuters) - The United States has awarded Chiron Corp. a $62.5 million contract to produce millions of doses of vaccine against the H5N1 strain of avian flu, U.S. Health and Human Services Secretary Michael Leavitt said on Thursday. Chiron shares were up 52 cents at $43.45 in afternoon Nasdaq trading. The vaccine will be a "pre-pandemic" formulation that Chiron and other companies have been working on for more than a year now, Chiron said. Doctors and health officials hope...

2005-10-17 17:55:00

By Deena Beasley LOS ANGELES (Reuters) - Chiron Corp. on Monday said its U.S. flu vaccine deliveries, and its net income, will fall short of expectations this year due to production delays at its British manufacturing plant. Chief Executive Howard Pien, speaking on a conference call, said the plant would produce fewer than 18 million doses for the 2005 to 2006 flu season, down from the company's previous estimate of 18 million to 26 million doses. He said the plant's total capacity for the...

2005-10-12 18:58:51

By Lisa Richwine WASHINGTON (Reuters) - Chiron Corp. may begin shipments within days of its first influenza vaccine since last year's contamination problems that abruptly cut the U.S. supply in half, the company said on Wednesday. U.S. regulators cleared three lots, or about 1.5 million doses, of Chiron's flu vaccine for sale, company spokeswoman Alison Marquiss said. Chiron still needs to complete final internal tests before sending the vaccine to distributors, she said. "We...

2005-08-31 12:16:26

WASHINGTON (Reuters) - U.S. health officials approved a new flu vaccine on Wednesday in hopes of bolstering supplies after last season's shortage, but said more work is needed before another supplier may be able to resume sales. The new vaccine, made by GlaxoSmithKline Plc, aims to fill the void left after rival Chiron Corp. lost its license and could not deliver half the anticipated U.S. supply during the 2004-2005 flu season. "Having more manufacturers of influenza vaccine licensed...

2005-08-31 09:00:00

NEW YORK (Reuters) - Chiron Corp., which last year suspended U.S. sales of its flu vaccine because of contamination problems at its plant in England, on Wednesday said it hopes to supply the vaccine in the 2005-2006 flu season following a favorable inspection of the plant by U.S. regulators. The U.S.-based company's manufacturing license for its Fluvirin vaccine was withdrawn last October because of contamination problems at the factory in Liverpool, depriving the United States of almost half...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related